ReviewInternational journal of molecular sciences2018
Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Once-weekly somapacitan vs. daily norditropin in GHD: a systematic review and meta-analysis of efficacy and safety in children and adults.Endocrine · 2026Pooled it
- GH Stimulation testing is unnecessary in patients with hypothalamic-pituitary disease, preserved pituitary function, and IGF-I SDS ≥ 0.Pituitary · 2026Article
- The Chronobiology of Hormone Administration: "Doctor, What Time Should I Take My Medication?"Endocrine reviews · 2025Review
- Prevalence and risk of complications in untreated patients with adult growth hormone deficiency.Pituitary · 2025Article
- Clinical and genetic features of childhood-onset congenital combined pituitary hormone deficiency: a retrospective, single-center cohort study.Annals of pediatric endocrinology & metabolism · 2024Article
- Bone mineral density in adults growth hormone deficiency with different ages of onset: a real-world retrospective study.Endocrine · 2024Article
- Baseline Clinical Factors Associated with Cessation of Growth Hormone Therapy in Patients with Severe Growth Hormone Deficiency - Real World Evidence.International journal of endocrinology and metabolism · 2024Article
- Growth hormone and radiation therapy: friend, foe, or both?Endocrine-related cancer · 2024Review
- Case Report: Plummer's adenoma in Prader-Willi syndrome.Frontiers in pediatrics · 2024Article
- The risk patients with AGHD have of developing CVD.International journal of cardiology. Cardiovascular risk and prevention · 2023Article
- Malignancies in Prader-Willi Syndrome: Results From a Large International Cohort and Literature Review.The Journal of clinical endocrinology and metabolism · 2023Review
- Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.Pituitary · 2023Article
- Accelerating digital health literacy for the treatment of growth disorders: The impact of a massive open online course.Frontiers in public health · 2023Article
- Copeptin in Growth Hormone-Treated Patients.Journal of clinical medicine · 2022Article
- Osteoporosis in Childhood Cancer Survivors: Physiopathology, Prevention, Therapy and Future Perspectives.Cancers · 2022Review
- New insight into the importance of formulation variables on parenteral growth hormone preparations: potential effect on the injection-site pain.Frontiers in endocrinology · 2022Review
- The Proteomic Signature of Recombinant Growth Hormone in Recreational Athletes.Journal of the Endocrine Society · 2021Article
- Thyroid-related ophthalmopathy development in concurrence with growth hormone administration.BMC endocrine disorders · 2021Article
- Targeting Energy Expenditure-Drugs for Obesity Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Circulating levels of growth hormone in postural orthostatic tachycardia syndrome.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacological treatment of growth hormone deficiency (GHD) in adults began in clinical practice more than 20 years ago. Since then, a great volume of experience has been accumulated on its effects on the symptoms and biochemical alterations that characterize this hormonal deficiency. The effects on body composition, muscle mass and strength, exercise capacity, glucose and lipid profile, bone metabolism, and quality of life have been fully demonstrated. The advance of knowledge has also taken place in the biological and molecular aspects of the action of this hormone in patients who have completed longitudinal growth. In recent years, several epidemiological studies have reported interesting information about the long-term effects of GH replacement therapy in regard to the possible induction of neoplasms and the potential development of diabetes. In addition, GH hormone receptor polymorphism could potentially influence GH therapy. Long-acting GH are under development to create a more convenient GH dosing profile, while retaining the excellent safety, efficacy, and tolerability of daily GH. In this article we compile the most recent data of GH replacement therapy in adults, as well as the molecular aspects that may condition a different sensitivity to this treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.